Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Cytokine Release Syndrome (CRS) Grading

    Assesses severity of CRS in patients on immunotherapy.

    INSTRUCTIONS

    Use in patients receiving immunotherapy for cancer.

    When to Use
    Pearls/Pitfalls
    Why Use

    Patients receiving immunotherapy for cancer with signs of cytokine-mediated immunological reactions and multi-organ dysfunction.

    • Do not forget coagulopathy as organ dysfunction.

    • High-dose vasopressors need to be on board for ≥3 hours in order to be assigned grade 3.

    • Consider corticosteroids at 24 hours if no improvement.

    • Most patients receiving immunological therapies have complicated ongoing processes and require specialized care. Clinical expertise, vigilance, and frequent follow-up are key to recognizing CRS and not attributing signs and symptoms to an alternate cause (e.g. infection).

    Helps guide interventions for patients receiving immunological therapies for cancer.

    Symptoms not life-threatening; only symptomatic treatment required (fever, nausea, fatigue, headache, myalgias, malaise)
    Moderate intervention required for response: oxygen requirement <40%, hypotension responsive to fluids, low dose of one pressor, or grade 2 organ toxicity
    Aggressive intervention required for response: oxygen requirement ≥40%, hypotension requiring high dose/multiple pressors, grade 3 organ toxicity, or grade 4 transaminitis
    Life-threatening symptoms: ventilator required, or grade 4 organ toxicity (excluding transaminitis)
    Death

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    OTHER

    About the Creator

    Other creator.

    About the Creator
    OTHER